A new real-world study conducted by Truveta Research has placed Eli Lilly’s blockbuster weight loss drug Mounjaro as more effective for weight loss purposes than the market’s other mega-popular option, Novo Nordisk’s Ozempic.
According to the study, patients treated on Mounjaro were more likely to lose 5%, 10% and 15% of overall body weight than those on Ozempic.
Likewise, Mounjaro users reported losing more body weight across three months, six months and a year than those taking Ozempic.
However, despite their growing reputation as weight loss drugs, both Mounjaro and Ozempic are currently only approved by the U.S. Food and Drug Administration for the treatment of Type 2 Diabetes.
